Analytical Data
-
基因名
MMAE
- Application
-
别名
MMAE；(3R)-3-[(carboxymethyl)amino]fatty acid oxygenase/decarboxylase
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
B2HKM3
-
表达区间
1-289aa
-
氨基酸序列
MTLNVKGEGLGAQITGVDPKNLDDITTDEIRDIVYANKLVILKDVNPSPEEFLKLGKIVGQIVPYYEPMYHHEDHPEIFVSSTEEGQGVPKTGAFWHIDYMFMPEPFAFSMVLPLAVPGHDRGTYFIDLAKVWQSLPAAQQAPARGTLSTHDPRRHIKIRPSDVYRPIGEVWDEISRATPPIKWPTVIRHPKTGEEILYICATGTTKIEDKDGNLVDPAVLAELLAATGQLDPEYNSPFIHTQHYEVGDIILWDNRVLMHRAKHGTASGTLTTYRLTMLDGLETPGYPA
-
分子量
32.3 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MMAE, or Monomethyl Auristatin E, is a potent tubulin inhibitor that has gained significant attention in the field of targeted cancer therapy, particularly in the context of antibody-drug conjugates (ADCs). The use of MMAE is particularly promising due to its ability to selectively disrupt the microtubule network in cancer cells, leading to cell cycle arrest and apoptosis. Research into MMAE-recombinant proteins aims to enhance the therapeutic efficacy and specificity of ADCs by improving the delivery of MMAE to tumor tissues while minimizing off-target effects. The incorporation of MMAE into antibody constructs facilitates the targeted delivery of this cytotoxic agent directly to cancer cells, leveraging the specificity of antibodies for tumor-associated antigens. This innovative approach not only holds potential for treating various malignancies but also aims to overcome challenges associated with traditional chemotherapy, such as systemic toxicity and drug resistance. Recent studies have focused on optimizing the conjugation techniques and evaluating the pharmacokinetics and biodistribution of MMAE-recombinant proteins, paving the way for the development of next-generation ADCs. As the understanding of cancer biology and drug delivery mechanisms advances, ongoing research into MMAE and its applications in targeted therapies continues to unveil new possibilities for improving patient outcomes in oncology.
